SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2013

SEGMENT INFORMATION [Abstract]

SEGMENT INFORMATION

NOTE 4. SEGMENT INFORMATION

We operate in one business segment: the research, development and commercialization of pharmaceutical products.  Our corporate headquarters in the United States collects product sales, licensing fees, royalties, and sponsored research revenues from our arrangements with external customers and licensees.  Our entire business is managed by a single management team, which reports to the Chief Executive Officer.

Our revenues are currently derived primarily from five licensees for international activities and our domestic sales activities of Altrazeal®.

Revenues per geographic area, along with relative percentages of total revenues, for the three and nine months ended September 30 are summarized as follows:

	Three Months Ended September 30,										Nine Months Ended September 30,
Revenues	2013		%			2012		%			2013		%			2012		%
Domestic	$	17,197		16	%	$	57,179		64	%	$	54,594		23	%	$	155,633		76	%
International		93,383		84	%		31,743		36	%		186,914		77	%		49,505		24	%
Total	$	110,580		100	%	$	88,922		100	%	$	241,508		100	%	$	205,138		100	%

A significant portion of our revenues are derived from a few major customers. Customers with greater than 10% of total sales, along with their relative percentage of all sales, for the three and nine months ended September 30 are represented on the following table:

			Three Months Ended September 30,		Nine Months Ended September 30,
Customers		Product	2013	2012	2013	2012
	Customer A	Altrazeal®	70%	29%	66%	15%
	Customer B	Aphthasol®	---	19%	---	24%
	Total		70%	48%	66%	39%